Evolution of the cardiac function during the follow-up of the anticancer immunotherapy inhibiting PD-1. IMMUNOCARD

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517403-36-00

Enrollment

Registered

2024-10-07

Start date

2018-04-09

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Evolution of left ventricular function measured by the global longitudinal strain value.

Interventions

DRUGNIVOLUMAB

DRUGPEMBROLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Evolution of left ventricular function measured by the global longitudinal strain value.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026